Lung Treatment Medicine ‘PNEUMOSTEM’ designated Orphan Drug by US FDA

Lung disease stem cell drug designated ‘orphan drug in development stage’

Lung disease stem cell treatment drug ‘PNEUMOSTEM’ application for US clinical trial

Administration of lung disease medicine ‘PNEUMOSTEM’ started in U.S. clinical trial

Administration of lung disease medicine ‘PNEUMOSTEM’ in clinical trial completed

The only Korean company invited to North American Rare Medicine conference

Lung disease medicine, ‘PNEUMOSTEM’ was designated as ‘Orphan Drug’ in Europe

MEDIPOST announced extension plans in US ’2015 Stem Cell Meeting on the Mesa’

‘PNEUMOSTEM’ selected as the ‘Newly developed and promising medical technology’ by National evidence based healthcare collaborating agency

MEDIPOST Obtains Patent in Canada for its ‘PNEUMOSTEM’ Used to Treat Lung Diseases

MEDIPOST receives US Patent for ‘PNEUMOSTEM’ for Treating Lung Disease

MEDIPOST Completes Phase 1 and 2 Clinical Trials with its Lung Disease Treatment Drug ‘PNEUMOSTEM’ in US